Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
685 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Myelodysplastic Syndrome - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H2 2015', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myelodysplastic Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myelodysplastic Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myelodysplastic Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 11 Introduction 12 Global Markets Direct Report Coverage 12 Myelodysplastic Syndrome Overview 13 Therapeutics Development 14 Pipeline Products for Myelodysplastic Syndrome - Overview 14 Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis 15 Myelodysplastic Syndrome - Therapeutics under Development by Companies 16 Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 23 Myelodysplastic Syndrome - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Myelodysplastic Syndrome - Products under Development by Companies 27 Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 35 Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 36 4SC AG 36 Acceleron Pharma, Inc. 37 Actinium Pharmaceuticals, Inc. 38 Advancell 39 Agios Pharmaceuticals, Inc. 40 Alnylam Pharmaceuticals, Inc. 41 Altor BioScience Corporation 42 Amgen Inc. 43 Apogenix GmbH 44 Arno Therapeutics, Inc. 45 Arog Pharmaceuticals, Inc. 46 Array BioPharma Inc. 47 Astex Pharmaceuticals, Inc. 48 Atara Biotherapeutics, Inc. 49 Bellicum Pharmaceuticals, Inc. 50 Bio-Path Holdings, Inc. 51 BioLineRx, Ltd. 52 Boehringer Ingelheim GmbH 53 Boryung Pharmaceutical Co., Ltd. 54 Boston Biomedical, Inc. 55 Bristol-Myers Squibb Company 56 Celator Pharmaceuticals, Inc. 57 Celgene Corporation 58 Celldex Therapeutics, Inc. 59 Cellerant Therapeutics, Inc. 60 Celyad SA 61 Clevexel Pharma SAS 62 Concert Pharmaceuticals, Inc. 63 Constellation Pharmaceuticals, Inc. 64 Cornerstone Pharmaceuticals, Inc. 65 CrystalGenomics, Inc. 66 CTI BioPharma Corp. 67 Cyclacel Pharmaceuticals, Inc. 68 Daiichi Sankyo Company, Limited 69 DiNonA Inc. 70 Eisai Co., Ltd. 71 Eleos Inc. 72 Eli Lilly and Company 73 EpiZyme, Inc. 74 F. Hoffmann-La Roche Ltd. 75 FORMA Therapeutics, Inc. 76 Fujifilm Corporation 77 Gamida Cell Ltd. 78 IGF Oncology, LLC. 79 ImmunoGen, Inc. 80 Incyte Corporation 81 Juno Therapeutics Inc. 82 JW Pharmaceutical Corporation 83 Kainos Medicine, Inc. 84 KaloBios Pharmaceuticals, Inc. 85 Karyopharm Therapeutics, Inc. 86 Kiadis Pharma B.V. 87 Kyowa Hakko Kirin Co., Ltd. 88 Les Laboratoires Servier SAS 89 Lixte Biotechnology Holdings, Inc. 90 medac GmbH 91 MedImmune, LLC 92 MEI Pharma, Inc. 93 Merck & Co., Inc. 94 Merus B.V. 95 Millennium Pharmaceuticals, Inc. 96 Mirati Therapeutics Inc. 97 Mirna Therapeutics, Inc. 98 Nemucore Medical Innovations, Inc. 99 Novartis AG 100 Onconova Therapeutics, Inc. 101 Opsona Therapeutics Limited 102 OXiGENE, Inc. 103 Pfizer Inc. 104 Pharma Mar, S.A. 105 Regen BioPharma, Inc. 106 Rich Pharmaceuticals, Inc. 107 Stemline Therapeutics, Inc. 108 Sumitomo Dainippon Pharma Co., Ltd. 109 Sunesis Pharmaceuticals, Inc. 110 Syndax Pharmaceuticals, Inc. 111 Synta Pharmaceuticals Corp. 112 Targazyme, Inc. 113 TetraLogic Pharmaceuticals 114 Teva Pharmaceutical Industries Limited 115 Threshold Pharmaceuticals, Inc. 116 Tragara Pharmaceuticals, Inc. 117 Myelodysplastic Syndrome - Therapeutics Assessment 118 Assessment by Monotherapy Products 118 Assessment by Combination Products 119 Assessment by Target 120 Assessment by Mechanism of Action 128 Assessment by Route of Administration 135 Assessment by Molecule Type 137 Drug Profiles 139 (cytarabine hydrochloride + daunorubicin hydrochloride) - Drug Profile 139 (decitabine + E-7727) - Drug Profile 142 4SC-202 - Drug Profile 144 765IGF-MTX - Drug Profile 146 acadesine - Drug Profile 147 AG-120 - Drug Profile 149 ALN-HPN - Drug Profile 151 alpelisib - Drug Profile 152 ALT-803 - Drug Profile 154 Antisense RNAi Oligonucleotide to Inhibit NR2F6 Protein for Oncology - Drug Profile 157 AR-42 - Drug Profile 158 asinercept - Drug Profile 160 atezolizumab - Drug Profile 162 ATIR-101 - Drug Profile 166 azacitidine - Drug Profile 168 BBMPI-03 - Drug Profile 172 BI-836858 - Drug Profile 173 binimetinib - Drug Profile 174 birinapant - Drug Profile 179 BL-8040 - Drug Profile 182 BLI-1301 - Drug Profile 184 bortezomib - Drug Profile 185 BP-100101 - Drug Profile 191 BPX-501 - Drug Profile 193 BR-05001 - Drug Profile 195 CC-90007 - Drug Profile 196 CDX-1401 - Drug Profile 199 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 201 Cell Therapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology - Drug Profile 202 Cell Therapy to Target WT1 for Cancer - Drug Profile 203 cenersen sodium - Drug Profile 204 CG-200745 - Drug Profile 206 CIGB-300 - Drug Profile 207 CMCS-1 - Drug Profile 209 CPI-0610 - Drug Profile 211 CPI-613 - Drug Profile 212 crenolanib besylate - Drug Profile 214 CSC-012 - Drug Profile 216 CTP-221 - Drug Profile 217 CVXL-0056 - Drug Profile 218 CWP-291 - Drug Profile 219 darbepoetin alfa - Drug Profile 221 dasatinib - Drug Profile 223 decitabine - Drug Profile 226 Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 229 Dendritic Cell Therapy for Oncology - Drug Profile 230 Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 231 DNP-001 - Drug Profile 232 DS-3032 - Drug Profile 233 DSP-7888 - Drug Profile 234 durvalumab - Drug Profile 235 E-6201 - Drug Profile 239 eltrombopag olamine - Drug Profile 241 entinostat - Drug Profile 244 epacadostat - Drug Profile 248 erismodegib - Drug Profile 250 everolimus - Drug Profile 253 evofosfamide - Drug Profile 259 FF-10501 - Drug Profile 267 FT-1101 - Drug Profile 268 galunisertib - Drug Profile 269 ganetespib - Drug Profile 271 Gene Therapy for Oncology - Drug Profile 276 glasdegib - Drug Profile 277 guadecitabine - Drug Profile 279 HDM-201 - Drug Profile 283 Hu8F4 - Drug Profile 284 IMGN-779 - Drug Profile 285 indisulam - Drug Profile 286 Iomab-B - Drug Profile 288 ixazomib citrate - Drug Profile 290 JTCR-016 - Drug Profile 294 KB-004 - Drug Profile 295 KHK-2823 - Drug Profile 297 KM-101 - Drug Profile 298 LB-100 - Drug Profile 299 lenalidomide - Drug Profile 301 lirilumab - Drug Profile 306 lurbinectedin - Drug Profile 308 luspatercept - Drug Profile 311 MCLA-
List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H2 2015 23 Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2015 24 Number of Products under Development by Companies, H2 2015 26 Number of Products under Development by Companies, H2 2015 (Contd..1) 27 Number of Products under Development by Companies, H2 2015 (Contd..2) 28 Number of Products under Development by Companies, H2 2015 (Contd..3) 29 Number of Products under Development by Companies, H2 2015 (Contd..4) 30 Number of Products under Development by Companies, H2 2015 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2015 32 Comparative Analysis by Late Stage Development, H2 2015 33 Comparative Analysis by Clinical Stage Development, H2 2015 34 Comparative Analysis by Early Stage Development, H2 2015 35 Products under Development by Companies, H2 2015 36 Products under Development by Companies, H2 2015 (Contd..1) 37 Products under Development by Companies, H2 2015 (Contd..2) 38 Products under Development by Companies, H2 2015 (Contd..3) 39 Products under Development by Companies, H2 2015 (Contd..4) 40 Products under Development by Companies, H2 2015 (Contd..5) 41 Products under Development by Companies, H2 2015 (Contd..6) 42 Products under Development by Companies, H2 2015 (Contd..7) 43 Products under Investigation by Universities/Institutes, H2 2015 44 Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2015 45 Myelodysplastic Syndrome - Pipeline by Acceleron Pharma, Inc., H2 2015 46 Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 47 Myelodysplastic Syndrome - Pipeline by Advancell, H2 2015 48 Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals, Inc., H2 2015 49 Myelodysplastic Syndrome - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 50 Myelodysplastic Syndrome - Pipeline by Altor BioScience Corporation, H2 2015 51 Myelodysplastic Syndrome - Pipeline by Amgen Inc., H2 2015 52 Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H2 2015 53 Myelodysplastic Syndrome - Pipeline by Arno Therapeutics, Inc., H2 2015 54 Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals, Inc., H2 2015 55 Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc., H2 2015 56 Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 57 Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics, Inc., H2 2015 58 Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 59 Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings, Inc., H2 2015 60 Myelodysplastic Syndrome - Pipeline by BioLineRx, Ltd., H2 2015 61 Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2015 62 Myelodysplastic Syndrome - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015 63 Myelodysplastic Syndrome - Pipeline by Boston Biomedical, Inc., H2 2015 64 Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2015 65 Myelodysplastic Syndrome - Pipeline by Celator Pharmaceuticals, Inc., H2 2015 66 Myelodysplastic Syndrome - Pipeline by Celgene Corporation, H2 2015 67 Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics, Inc., H2 2015 68 Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics, Inc., H2 2015 69 Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2015 70 Myelodysplastic Syndrome - Pipeline by Clevexel Pharma SAS, H2 2015 71 Myelodysplastic Syndrome - Pipeline by Concert Pharmaceuticals, Inc., H2 2015 72 Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 73 Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015 74 Myelodysplastic Syndrome - Pipeline by CrystalGenomics, Inc., H2 2015 75 Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp., H2 2015 76 Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 77 Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 78 Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H2 2015 79 Myelodysplastic Syndrome - Pipeline by Eisai Co., Ltd., H2 2015 80 Myelodysplastic Syndrome - Pipeline by Eleos Inc., H2 2015 81 Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H2 2015 82 Myelodysplastic Syndrome - Pipeline by EpiZyme, Inc., H2 2015 83 Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 84 Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics, Inc., H2 2015 85 Myelodysplastic Syndrome - Pipeline by Fujifilm Corporation, H2 2015 86 Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd., H2 2015 87 Myelodysplastic Syndrome - Pipeline by IGF Oncology, LLC., H2 2015 88 Myelodysplastic Syndrome - Pipeline by ImmunoGen, Inc., H2 2015 89 Myelodysplastic Syndrome - Pipeline by Incyte Corporation, H2 2015 90 Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc., H2 2015 91 Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corporation, H2 2015 92 Myelodysplastic Syndrome - Pipeline by Kainos Medicine, Inc., H2 2015 93 Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015 94 Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 95 Myelodysplastic Syndrome - Pipeline by Kiadis Pharma B.V., H2 2015 96 Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 97 Myelodysplastic Syndrome - Pipeline by Les Laboratoires Servier SAS, H2 2015 98 Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015 99 Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2015 100 Myelodysplastic Syndrome - Pipeline by MedImmune, LLC, H2 2015 101 Myelodysplastic Syndrome - Pipeline by MEI Pharma, Inc., H2 2015 102 Myelodysplastic Syndrome - Pipeline by Merck & Co., Inc., H2 2015 103 Myelodysplastic Syndrome - Pipeline by Merus B.V., H2 2015 104 Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 105 Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc., H2 2015 106 Myelodysplastic Syndrome - Pipeline by Mirna Therapeutics, Inc., H2 2015 107 Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations, Inc., H2 2015 108 Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2015 109 Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics, Inc., H2 2015 110 Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Limited, H2 2015 111 Myelodysplastic Syndrome - Pipeline by OXiGENE, Inc., H2 2015 112 Myelodysplastic Syndrome - Pipeline by Pfizer Inc., H2 2015 113 Myelodysplastic Syndrome - Pipeline by Pharma Mar, S.A., H2 2015 114 Myelodysplastic Syndrome - Pipeline by Regen BioPharma, Inc., H2 2015 115 Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals, Inc., H2 2015 116 Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics, Inc., H2 2015 117 Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 118 Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2015 119 Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 120 Myelodysplastic Syndrome - Pipeline by Synta Pharmaceuticals Corp., H2 2015 121 Myelodysplastic Syndrome - Pipeline by Targazyme, Inc., H2 2015 122 Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H2 2015 123 Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 124 Myelodysplastic Syndrome - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 125 Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015 126 Assessment by Monotherapy Products, H2 2015 127 Assessment by Combination Products, H2 2015 128 Number of Products by Stage and Target, H2 2015 130 Number of Products by Stage and Mechanism of Action, H2 2015 138 Number of Products by Stage and Route of Administration, H2 2015 145 Number of Products by Stage and Molecule Type, H2 2015 147 Myelodysplastic Syndrome Therapeutics - Recent Pipeline Updates, H2 2015 431 Myelodysplastic Syndrome - Dormant Projects, H2 2015 671 Myelodysplastic Syndrome - Dormant Projects (Contd..1), H2 2015 672 Myelodysplastic Syndrome - Dormant Projects (Contd..2), H2 2015 673 Myelodysplastic Syndrome - Dormant Projects (Contd..3), H2 2015 674 Myelodysplastic Syndrome - Dormant Projects (Contd..4), H2 2015 675 Myelodysplastic Syndrome - Discontinued Products, H2 2015 676 Myelodysplastic Syndrome - Discontinued Products (Contd..1), H2 2015 677
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
